Dublin, May 08, 2018 -- The "Exosomes & Liquid Biopsies Europe 2018" conference has been added to ResearchAndMarkets.com's offering.
The Exosomes and Liquid Biopsies Europe 2018 Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby circulating biomarkers of various classes are being evaluated for their potential to be developed into minimally-invasive diagnostics and liquid biopsies for cancer as well as other disease classes.
This Exosomes and Liquid Biopsies 2018 Conference focuses primarily on biofluid-based molecular biomarkers, such as circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs), protein-based circulating biomarkers, and exosomes/extracellular vesicles (EVs). There is much interest in the potential of ctDNA and EVs for developing biological fluid-based biopsies (such as using plasma, urine, or other biofluids) and the presenters in this conference bring together the most up-to-date information and current state-of-the-field.
The conference further explores the potential of various minimally-invasive circulating biomarker classes, such as circulating-free DNA (cfDNA), CTCs, and Extracellular Vesicles (EVs), for development of novel diagnostics for early patient monitoring.
Another component of this conference is the exploration of the science behind Exosomes and Extracellular Vesicles - Diagnostic and Therapeutic Potential.
The conference is being held in Rotterdam, The Netherlands-an excellent venue for networking with connections across The Netherlands, Europe and Worldwide. The conference includes an exhibition bringing together companies from around the world focused on developing technologies, tools, products and services serving the liquid biopsy field.
The Conference Chairman and Chief Scientific Advisor is Professor Dominique de Kleijn, Professor, University Medical Center Utrecht, The Netherlands.
Agenda:
- Circulating Tumor Cells (CTCs): Potential for Development of Liquid Biopsies
- Circulating Tumor DNA (ctDNA): Potential for Development of Liquid Biopsies
- Emerging Technologies and Emerging Companies Showcase
- Exosomes and Extracellular Vesicles (EVs): Potential for Development of Liquid Biopsies
- Exosomes as Delivery Vehicles and Therapeutic Applications of Exosomes
- Extracellular Nucleic Acids in the Circulation: Circulating Free DNA, Extracellular RNAs and Circulating microRNAs/Long Non-Coding RNAs
- Extracellular Vesicles (EV) in Cancer, Cardiovascular Disease, Neurological Diseases and Beyond
- Grants and Awards across the EU for Exosomes and Liquid Biopsy Research
- Regulatory Landscape for Liquid Biopsies (EU, US and Asia/Pacific)
For more information about this conference visit https://www.researchandmarkets.com/research/bscdcc/exosomes_and?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



